SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION vs Imbio PHA (4.0.0)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

by DIACOUSTIC MEDICAL DEVICES (PTY)

Imbio PHA (4.0.0)

by Imbio (a subsidiary of 4DMedical)

AI Verdict

Tool A focuses on the acoustic analysis of heart murmurs using an electronic stethoscope to aid in differentiating between physiological and pathological sounds. In contrast, Tool B specializes in processing CT pulmonary angiogram scans to automatically measure cardiac structures for the assessment of right ventricular dilation, pulmonary embolism, and hypertension. While both are FDA-cleared AI tools in cardiology, their fundamental input modalities and specific diagnostic applications are distinct, making them suitable for different clinical use cases.

Choose SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION if…

Choose SensiCardiac Mobi if you need a mobile, AI-powered tool to enhance your physical examination by analyzing acoustic heart signals in real-time. This application is ideal for physicians seeking immediate decision support to differentiate between physiological and pathological heart murmurs at the point of care, complementing their auscultation skills.

View SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION →

Choose Imbio PHA (4.0.0) if…

Choose Imbio PHA if your workflow involves interpreting CT pulmonary angiogram (CTPA) scans and requires automated, quantitative analysis of cardiac structures. This software is best suited for radiologists and cardiologists who need to quickly assess right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension based on advanced imaging data.

View Imbio PHA (4.0.0) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION	Imbio PHA (4.0.0)
Pricing	Contact for pricing	Unknown
Deployment	Hosted server environment (Linux OS) with a mobile application interface	Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel).
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

SensiCardiac Mobi (Tool A) offers a mobile application for direct, real-time auscultation at the point of care, which provides an intuitive and immediate user experience for clinicians during patient examinations. This direct interaction via a mobile device can be perceived as more user-friendly for a broader range of medical professionals compared to integration into complex imaging workflows.

Clinical Value

Tie

Both tools are FDA-cleared and provide significant clinical value in their respective specialties. SensiCardiac Mobi (Tool A) assists in diagnosing heart murmurs and has been validated in clinical studies, while Imbio PHA (Tool B) offers quantitative measurements from CTPA scans for risk stratification in pulmonary embolism and hypertension, also supported by clinical studies.

Pricing & Value

Tie

Neither SensiCardiac Mobi (Tool A) nor Imbio PHA (Tool B) provide public pricing information, both requiring direct contact for details. Without any transparent pricing, it is impossible to conduct a meaningful comparison of their cost or overall value proposition.

Enterprise Readiness

Imbio PHA (4.0.0)

Imbio PHA (Tool B) demonstrates higher enterprise readiness with flexible deployment options including cloud, on-premise, or via partners, and explicit integration with native DICOM tools and workflows. This offers greater adaptability and seamless integration into existing hospital imaging systems compared to Tool A's more general 'hosted server environment' and mobile application focus.

Innovation

SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

SensiCardiac Mobi (Tool A) presents a more innovative application of AI by leveraging a mobile application for real-time acoustic heart signal analysis and heart murmur differentiation directly at the point of care. This approach to immediate clinical decision support in auscultation is distinct compared to Imbio PHA's (Tool B) use of AI in medical image processing, which is a more established field.

Support & Docs

Imbio PHA (4.0.0)

Imbio PHA (Tool B) offers a more transparent and accessible support structure, including dedicated contact information (phone, email), an online case submission system, and explicit mention of available user manuals and support documents. SensiCardiac Mobi (Tool A) lacks readily available public information regarding its support offerings and documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION	Imbio PHA (4.0.0)
Name	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION	Imbio PHA (4.0.0)
Description	SensiCardiac Mobi is an FDA-cleared AI-powered mobile application that assists physicians in diagnosing heart murmurs by analyzing acoustic heart signals from an electronic stethoscope to differentiate between physiological and pathological sounds.	Imbio PHA (4.0.0) is an FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.
Company	DIACOUSTIC MEDICAL DEVICES (PTY)	Imbio
Primary Data Input	Acoustic heart signals from an electronic stethoscope	CT pulmonary angiogram (CTPA) scans
Core Functionality	Analyzes heart sounds using the Sensi Diagnostic Heart Murmur Algorithm; distinguishes between normal/physiological and pathological heart murmurs; identifies S1, S2, and suspected murmurs.	Automated measurement of right and left ventricle diameters, main pulmonary artery and aorta diameters; calculates RV/LV and PA/Ao ratios.
Target Specialties	Cardiology, Internal Medicine, Pediatrics	Cardiology, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION and Imbio PHA (4.0.0).

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How does each tool integrate into existing clinical workflows for patient assessment and diagnosis?

SensiCardiac Mobi is a mobile application that acquires and records acoustic heart signals using a compatible electronic stethoscope, operating as decision support to complement physician assessment. Imbio PHA integrates with native DICOM tools and workflows, providing rapid, fully-automated assessment of CTPA scans, generating annotated DICOM images and PDF summary reports that can be added to the patient study in PACS.

What is the depth of EHR integration for each tool, particularly regarding the transfer of findings and reports?

SensiCardiac Mobi captures and displays data on a mobile application, with the algorithm running on a hosted server environment, but direct EHR integration for findings transfer is not explicitly detailed in the provided information. Imbio PHA generates annotated DICOM images and PDF summary reports that are automatically delivered to the patient study in PACS, which can then be accessed by anyone with PACS access, implying a streamlined integration with imaging systems that often link to EHRs.

For which specific clinical scenarios or patient populations is each tool most optimally suited, given their distinct diagnostic focuses?

SensiCardiac Mobi is optimally suited for assisting physicians in diagnosing heart murmurs by differentiating physiological and pathological sounds, primarily for Cardiology, Internal Medicine, and Pediatrics. Imbio PHA is designed for assessing potential right ventricular dilation from CT pulmonary angiogram (CTPA) scans to aid in the diagnosis and risk stratification of pulmonary embolism and hypertension, making it suitable for Cardiology, Pulmonology, and Radiology specialties.

While specific performance metrics are not provided in the initial description, what level of diagnostic assistance or measurement precision can physicians expect from each tool's AI algorithms?

SensiCardiac Mobi's AI algorithm analyzes acoustic heart signals to distinguish between normal/physiological and pathological heart murmurs, identifying S1, S2, and suspected murmurs. Clinical experiments with a mobile application utilizing a similar AI algorithm have shown approximately 92% accuracy in detecting heart abnormalities, comparable to expert cardiologists. Imbio PHA utilizes AI algorithms for automated anatomical identification and measurement of cardiac structures from CTPA scans, providing precise measurements of right and left ventricle diameters, main pulmonary artery, and aorta, along with calculated RV/LV and PA/Ao ratios.

What is the expected learning curve for physicians and their teams to effectively incorporate each tool into their daily practice?

SensiCardiac Mobi involves using a mobile application for data capture and display with a compatible electronic stethoscope, suggesting a learning curve related to mobile app interaction and proper auscultation technique. Imbio PHA integrates with native DICOM tools and workflows, offering rapid, fully-automated assessment, which implies a potentially lower learning curve for initiating analysis within existing imaging review processes.

What are the key considerations for deploying each tool across multiple clinical sites or a larger healthcare system?

SensiCardiac Mobi relies on a mobile application and user-provided electronic stethoscopes, with the algorithm running on a hosted server environment, which may require coordinating compatible hardware and mobile device management across sites. Imbio PHA offers flexible deployment options including Cloud, Enterprise (on-premise), or via partners, and is designed to integrate with existing DICOM workflows, allowing for scalable implementation within diverse IT infrastructures.